Literature DB >> 8598225

The c-ets-1 proto-oncogene is a new early-response gene differentially regulated by cytokines and growth factors in human fibroblasts.

F Gilles1, M B Raes, D Stéhelin, B Vandenbunder, V Fafeur.   

Abstract

In various invasive human tumors, c-ets-1 mRNA was found to be selectively expressed in stromal fibroblasts. We have now investigated the possibility that soluble factors could regulate c-ets-1 expression in cultured human fibroblasts. We show that both conditioned media from tumor cell lines and a number of characterized cytokines and growth factors were able to induce c-ets-1 expression. TNF alpha and IL-1 alpha were the most potent c-ets-1 stimulators, inducing rapid (within 1 h) and long-lasting (19 h) increases of c-ets-1 mRNA and protein expression. In contrast, bFGF, EGF, and PDGF were mainly delayed stimulators, with maximal stimulation being detected by 19 h. In addition, these growth factors potentiated the rapid induction of c-ets-1 by TNF alpha. While all these factors were able to stimulate c-ets-1 expression, TGF beta was found to be ineffective. Using inhibitors of transcription and translation, we also found that increase of c-ets-1 mRNA by TNF alpha resulted from new transcription rather than from stabilization and did not require new protein synthesis. These results demonstrated that c-ets-1 is a new nuclear target for several factors and behaves as an early-response gene for TNF alpha.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8598225     DOI: 10.1006/excr.1996.0046

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Role of the Ets-1 transcription factor during activation of rat hepatic stellate cells in culture.

Authors:  T Knittel; D Kobold; J Dudas; B Saile; G Ramadori
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.

Authors:  D Tulasne; R Paumelle; K M Weidner; B Vandenbunder; V Fafeur
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

3.  c-ETS1 facilitates G1/S-phase transition by up-regulating cyclin E and CDK2 genes and cooperates with hepatitis B virus X protein for their deregulation.

Authors:  Anup Kumar Singh; Manickavinayaham Swarnalatha; Vijay Kumar
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

4.  Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines.

Authors:  C Gilles; M Polette; P Birembaut; N Brünner; E W Thompson
Journal:  Clin Exp Metastasis       Date:  1997-09       Impact factor: 5.150

5.  Allelic variation of Ets1 does not contribute to NK and NKT cell deficiencies in type 1 diabetes susceptible NOD mice.

Authors:  Margaret A Jordan; Lynn D Poulton; Julie M Fletcher; Alan G Baxter
Journal:  Rev Diabet Stud       Date:  2009-08-10

6.  Recombinant avian leukosis viruses of subgroup J isolated from field infected commercial layer chickens with hemangioma and myeloid leukosis possess an insertion in the E element.

Authors:  Xiaoping Wu; Kun Qian; Aijian Qin; Haiyu Shen; Pingping Wang; Wenjie Jin; Yassir Mohammed Eltahir
Journal:  Vet Res Commun       Date:  2010-07-31       Impact factor: 2.459

7.  Molecular events associated with epithelial to mesenchymal transition of nasopharyngeal carcinoma cells in the absence of Epstein-Barr virus genome.

Authors:  Jung-Chung Lin; Shuen-Kuei Liao; En-Huei Lee; Man-Shan Hung; Yiyang Sayion; Hung-Chang Chen; Chen-Chen Kang; Liang-Sheng Huang; Jaw-Ming Cherng
Journal:  J Biomed Sci       Date:  2009-11-24       Impact factor: 8.410

8.  Identification of genes involved in ceramide-dependent neuronal apoptosis using cDNA arrays.

Authors:  Charles Decraene; Bernard Brugg; Merle Ruberg; Eric Eveno; Christiane Matingou; Fariza Tahi; Jean Mariani; Charles Auffray; Geneviève Pietu
Journal:  Genome Biol       Date:  2002-07-31       Impact factor: 13.583

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.